Arndt Vogel, MD, PhD, Hannover Medical School, Hannover, Germany, discusses the IMMULAB study (NCT03753659), a trial-in-progress evaluating immunotherapy with pembrolizumab in combination with local ablation for patients with early-stage hepatocellular carcinoma (HCC). This investigation will evaluate the clinical activity of peri-interventional treatment with the anti-PD1 antibody pembrolizumab in HCC patients who are candidates for local ablation. This interview took place at the American Society of Clinical Oncology (ASCO) 2021 Virtual Meeting.